Efficacy and Safety of Coadministered Irbesartan and Atorvastatin in Patients With Hypertension and Hyperlipidemia

Trial Profile

Efficacy and Safety of Coadministered Irbesartan and Atorvastatin in Patients With Hypertension and Hyperlipidemia

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Atorvastatin/irbesartan (Primary) ; Atorvastatin; Irbesartan
  • Indications Hyperlipidaemia; Hypertension
  • Focus Therapeutic Use
  • Sponsors Hanmi Pharmaceutical
  • Most Recent Events

    • 11 Oct 2016 Primary endpoint has been met. (Change from baseline to 8 week in Blood Pressure. [ Time Frame: baseline and 8 week ] [ Designated as safety issue: No ]), according to results published in the Clinical Therapeutics.
    • 11 Oct 2016 Primary endpoint has been met. (Percent change from baseline to 8 week in LDL-Cholesterol [ Time Frame: baseline and 8 week ] [ Designated as safety issue: No ]), according to results published in the Clinical Therapeutics.
    • 11 Oct 2016 Results published in the Clinical Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top